China Resources Double-Crane: Controlling subsidiary’s sodium valproate oral solution has obtained the drug registration certificate

People’s Financial News, March 17 — China Resources Double-Crane (600062) announced on March 17 that its controlling subsidiary, Xiangzhong Pharmaceutical, has received the drug registration certificate for sodium valproate oral solution issued by the National Medical Products Administration. Sodium valproate oral solution is used for generalized, partial, or other types of epilepsy.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin